Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01272
|
|||||
| Drug Name |
Pyrimethamine
|
|||||
| Synonyms |
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine; AZT + Pyrimethamine combination; Aventis Brand of Pyrimethamine; BW 50-63; BW 5063; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprim (TN); Daraprime; Daraprin; Diaminopyritamin; EXR-101; Erbaprelina; Ethylpyrimidine; Fansidar (Pyrimethamine/Sulfadoxine); Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; Khloridin; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; M alocid; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Pirimetamina [INN-Spanish]; Pirimetamina [Spanish]; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethamine (JAN/USP/INN); Pyrimethamine (Pyr); Pyrimethamine Hcl; Pyrimethamine [USAN:INN:BAN:JAN]; Pyrimethaminum; Pyrimethaminum [INN-Latin]; RP 4753; TCMDC-123831; TCMDC-125860; Tindurin; Tindurine; Tinduring; WR 2978; Wellcome Brand of Pyrimethamine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Toxoplasmosis [ICD11: 1F57] | Approved | [1] | |||
| Actinomycosis [ICD11: 1C10] | Approved | [1] | ||||
| Isosporiasis [ICD11: 1A33.Z] | Approved | [1] | ||||
| Therapeutic Class |
Antimalarials
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H13ClN4
|
|||||
| Canonical SMILES |
CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl
|
|||||
| InChI |
InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)
|
|||||
| InChIKey |
WKSAUQYGYAYLPV-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 58-14-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 248.71 | Topological Polar Surface Area | 77.8 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9595
, 69611
, 602526
, 640729
, 640732
, 642442
, 642444
, 823186
, 855854
, 7437605
, 7847554
, 7886730
, 7980441
, 8027594
, 8027596
, 8149512
, 8153075
, 10321489
, 10528164
, 11112140
, 11335827
, 11361066
, 11363800
, 11366362
, 11368924
, 11372601
, 11374146
, 11377086
, 11406997
, 11455757
, 11462038
, 11466065
, 11467185
, 11484408
, 11485790
, 11488702
, 11491516
, 11492309
, 11494720
, 15221150
, 17389746
, 22395175
, 24870381
, 26611904
, 26679783
, 26747011
, 26747012
, 26751532
, 29224066
, 46505987
|
|||||
| ChEBI ID |
CHEBI:8673
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Pyrimethamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. | |||||
| 3 | Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.